PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.61%
Revenue growth 1.25-1.5x MRVL's 6.58%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
13.26%
Gross profit growth above 1.5x MRVL's 4.54%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-10.38%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-10.38%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-7.52%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.27%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-13.64%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-6.44%
Share reduction while MRVL is at 3.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
4.98%
Diluted share count expanding well above MRVL's 1.30%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-77.64%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-85.28%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
546.10%
10Y revenue/share CAGR 1.25-1.5x MRVL's 459.79%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
125.41%
5Y revenue/share CAGR under 50% of MRVL's 525.68%. Michael Burry would suspect a significant competitive gap or product weakness.
53.50%
3Y revenue/share CAGR under 50% of MRVL's 157.52%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
897.28%
10Y OCF/share CAGR above 1.5x MRVL's 329.50%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
12.51%
Below 50% of MRVL's 257.03%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
13.66%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
868.39%
Net income/share CAGR at 75-90% of MRVL's 1060.07%. Bill Ackman would press for strategic moves to boost long-term earnings.
179.23%
5Y net income/share CAGR 1.25-1.5x MRVL's 155.31%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
318.68%
Below 50% of MRVL's 1336.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
1311.12%
Below 50% of MRVL's 7355.62%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
176.58%
5Y equity/share CAGR above 1.5x MRVL's 8.56%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
52.65%
3Y equity/share CAGR above 1.5x MRVL's 34.92%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.97%
AR growth well above MRVL's 19.73%. Michael Burry fears inflated revenue or higher default risk in the near future.
35.94%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
12.85%
Asset growth above 1.5x MRVL's 2.81%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
17.94%
BV/share growth above 1.5x MRVL's 1.12%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
32.42%
R&D growth drastically higher vs. MRVL's 40.66%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
30.91%
SG&A growth well above MRVL's 51.85%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.